ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Follicular Lymphoma MORE >>

The combination of CC-122, an investigational pleiotropic pathway modulator, and the second-generation anti-CD20 antibody obinutuzumab induced strong responses in patients with relapsed or refractory follicular lymphoma.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.